Key Takeaways A pill to treat obesity caused liver injury in a clinical trialPfizer said it will stop developing the drug, called danuglipron, as a result Other alternatives to injectable obesity ...

Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are tirzepatide (Zepbound) and semaglutide (Wegovy). Semaglutide was originally ...

The maker of Ozempic and the weight loss drug Wegovy told the FDA on April 3 that counterfeit 1-milligram injections were ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

SYNT-101 offers a novel approach to weight loss by temporarily altering nutrient absorption in the small intestine. Unlike GLP-1 drugs, which are administered via injection and ...

Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial ...

The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant’s bid to win a slice of ...

For decades, the medical approach to treating obesity in children was the wait-and-see approach. But a new Canadian guideline ...